{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:21:38Z","timestamp":1768418498214,"version":"3.49.0"},"reference-count":33,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":108,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,9,22]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Despite advances in multiple sclerosis (MS) management, the need for more accurate biomarkers remains critical. Conventional MRI, while essential for diagnosis, prognosis and disease monitoring, has limitations in capturing the full complexity of disease progression. This paper aims to identify biomarkers likely to be available in clinical practice by 2028, define a prospective organisational follow-up model for patients with MS, explore organisational requirements and propose solutions to facilitate their implementation. These insights aim to inform and anticipate future discussions among policymakers regarding the adoption of prospective biomarkers into clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A multimethod qualitative design was employed, including a systematic literature review of 82 studies, two modified Delphi consensus processes and semistructured interviews with nine neurologists and three healthcare programming experts, applying the Structural, Technological, Organisational and Professional (STOP) framework. The STOP framework was used to assess structural, technological, organisational and professional requirements and to explore solutions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The research identified a prospective organisational follow-up model that integrates the most probable prospective biomarkers into clinical practice. The prospective organisational follow-up model defined an optimal testing frequency of Serum Neurofilament Light Chain and Glial Fibrillar Acidic Protein every 6 months, as well as Cognitive Tests and Optical Coherence Tomography every 12 months. Combining biomarkers and aligning them with MRI was seen as beneficial. Despite the validation of the model through a modified Delphi consensus process based on organisational feasibility and economic sustainability, structural and organisational challenges need to be addressed to ensure smoother integration into clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This article aims to define an organisational model for the integration of prospective biomarkers into clinical follow-up in MS. It also explores potential strategies to facilitate their transition from research settings to routine clinical practice. The proposed approach provides a framework with potential for replication across various care pathways.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjno-2025-001269","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:23:48Z","timestamp":1760700228000},"page":"e001269","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Organisational impact and patient management models for biomarker integration in multiple sclerosis care in Italy: the 0Tolerance project"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2516-1567","authenticated-orcid":false,"given":"Paolo","family":"Ragonese","sequence":"first","affiliation":[{"name":"Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Buscarinu","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs, University of Rome, La Sapienza Faculty of Pharmacy and Medicine, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cellerino","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Colombo","sequence":"additional","affiliation":[{"name":"Foundation National Neurological Institute Casimiro Mondino, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Frau","sequence":"additional","affiliation":[{"name":"Ospedale Roberto Binaghi, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Frigo","sequence":"additional","affiliation":[{"name":"San Gerardo Hospital, Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2313-8462","authenticated-orcid":false,"given":"Marco","family":"Puthenparampil","sequence":"additional","affiliation":[{"name":"Department of Neurosciences DNS, Multiple Sclerosis Centre, University Hospital\u2014Medical School, Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Rigoni","sequence":"additional","affiliation":[{"name":"Foundation National Neurological Institute Casimiro Mondino, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3948-2534","authenticated-orcid":false,"given":"Valeria","family":"Zancan","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs, University of Rome, La Sapienza Faculty of Pharmacy and Medicine, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Pinto","sequence":"additional","affiliation":[{"name":"IQVIA Italy, Milan, Lombardy, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Parretti","sequence":"additional","affiliation":[{"name":"IQVIA Italy, Milan, Lombardy, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Gazzaniga","sequence":"additional","affiliation":[{"name":"IQVIA Italy, Milan, Lombardy, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025101704051719000_7.2.e001269.1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/biomedicines11020606","article-title":"Serum Neurofilaments and OCT Metrics Predict EDSS-Plus Score Progression in Early Relapse-Remitting Multiple Sclerosis","volume":"11","author":"Tiu","year":"2023","journal-title":"Biomedicines"},{"key":"2025101704051719000_7.2.e001269.2","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s10072-023-07228-3","article-title":"Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials","volume":"45","author":"Schilke","year":"2024","journal-title":"Neurol Sci"},{"key":"2025101704051719000_7.2.e001269.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30959-X"},{"key":"2025101704051719000_7.2.e001269.4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/s41423-020-00618-z","article-title":"Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy","volume":"18","author":"Mansilla","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025101704051719000_7.2.e001269.5","unstructured":"AISM . Associazione Italiana Sclerosi Multipla. Barometro della Sclerosi Multipla e patologie correlate 2023. AISM. Barometro della Sclerosi Multipla e patologie correlate. 2023."},{"key":"2025101704051719000_7.2.e001269.6","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/brain\/awab241","article-title":"The potential of serum neurofilament as biomarker for multiple sclerosis","volume":"144","author":"Bittner","year":"2021","journal-title":"Brain (Bacau)"},{"key":"2025101704051719000_7.2.e001269.7","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519882279"},{"key":"2025101704051719000_7.2.e001269.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6569.2002.tb00136.x"},{"key":"2025101704051719000_7.2.e001269.9","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.856240","article-title":"Understanding Magnetic Resonance Imaging in Multiple Sclerosis (UMIMS): Development and Piloting of an Online Education Program About Magnetic Resonance Imaging for People With Multiple Sclerosis","volume":"13","author":"Freund","year":"2022","journal-title":"Front Neurol"},{"key":"2025101704051719000_7.2.e001269.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12021-5"},{"key":"2025101704051719000_7.2.e001269.11","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200206000-00003"},{"key":"2025101704051719000_7.2.e001269.12","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/brain\/awx185","article-title":"Towards personalized therapy for multiple sclerosis: prediction of individual treatment response","volume":"140","author":"Kalincik","year":"2017","journal-title":"Brain (Bacau)"},{"key":"2025101704051719000_7.2.e001269.13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1352458516676899","article-title":"Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts","volume":"23","author":"Sormani","year":"2017","journal-title":"Mult Scler"},{"key":"2025101704051719000_7.2.e001269.14","unstructured":"AISM . Associazione Italiana Sclerosi Multipla. Caratteristiche e dotazione dei Centri clinici. Available: https:\/\/aism.it\/caratteristiche-e-dotazione-dei-centri-clinici [Accessed 15 Mar 2024]."},{"key":"2025101704051719000_7.2.e001269.15","doi-asserted-by":"crossref","unstructured":"Filippi M , Gallo P , Gasperini C , et al . Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project. J Neurol 2025;272. doi:10.1007\/s00415-024-12749-8","DOI":"10.1007\/s00415-024-12749-8"},{"key":"2025101704051719000_7.2.e001269.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2025101704051719000_7.2.e001269.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2025101704051719000_7.2.e001269.18","first-page":"317","article-title":"The Delphi Method: Techniques and Applications","volume":"13","author":"Mahajan","year":"1976","journal-title":"J Mark Res"},{"key":"2025101704051719000_7.2.e001269.19","unstructured":"Cartabellotta A . Struttura, processo, esito. quali indicatori misurano la qualit\u00e0 dell\u2019assistenza sanitaria? GIMBE news."},{"key":"2025101704051719000_7.2.e001269.20","unstructured":"Cartabellotta A . L\u2019adattamento locale delle linee guida. Quando \u00e8 lecito modificare le raccomandazioni cliniche? GIMBE news."},{"key":"2025101704051719000_7.2.e001269.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"2025101704051719000_7.2.e001269.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00009-6"},{"key":"2025101704051719000_7.2.e001269.23","unstructured":"Burroni E . Centralizzazione dei test HPV di screening primario in Regione Toscana: stato dell\u2019arte e criticit\u00e0. ISPO (IStituto per lo Studio e la Prevenzione Oncologica); 2017. Available: https:\/\/www.gisci.it\/"},{"key":"2025101704051719000_7.2.e001269.24","unstructured":"ISPRO (Istituto per lo studio, la prevenzione e la rete oncologica) . Cosa significa centralizzazione? n.d. Available: https:\/\/www.ispro.toscana.it\/laboratorio\/centralizzazione"},{"key":"2025101704051719000_7.2.e001269.25","unstructured":"Istituto Superiore di Sanit\u00e0 . Basi Scientifiche per La Definizione Di Linee-Guida in Ambito Clinico per i Tumori Dell\u2019Et\u00e0 Pediatrica. 2018. Available: https:\/\/www.iss.it\/documents\/20126\/2390958\/TESTO_PEDIATRIA_FINALE_2.10.08.1227702748.pdf\/c3bcbfd1-d616-9a87-dd0d-d111e4264785?version=1.1&t=1575744726596&download=true"},{"key":"2025101704051719000_7.2.e001269.26","doi-asserted-by":"crossref","DOI":"10.1007\/s10544-019-0412-y","article-title":"A review of microsampling techniques and their social impact","volume":"21","author":"Lei","year":"2019","journal-title":"Biomed Microdevices"},{"key":"2025101704051719000_7.2.e001269.27","doi-asserted-by":"crossref","DOI":"10.5210\/ojphi.v4i2.4186","article-title":"A Web-Based System for Mapping Laboratory Networks: Analysis of GLaDMap Application","volume":"4","author":"Mukhi","year":"2012","journal-title":"Online J Public Health Inform"},{"key":"2025101704051719000_7.2.e001269.28","first-page":"2295","article-title":"Department of Global Public Health, Karolinska Institute, Stockholm 17177","volume":"17","author":"Sweden","year":"2024","journal-title":"Int J Ophthalmol"},{"key":"2025101704051719000_7.2.e001269.29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40942-024-00549-1","article-title":"AI-based support for optical coherence tomography in age-related macular degeneration","volume":"10","author":"Mares","year":"2024","journal-title":"Int J Retin Vitr"},{"key":"2025101704051719000_7.2.e001269.30","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.14.1.27","article-title":"Artificial Intelligence for Optical Coherence Tomography in Glaucoma","volume":"14","author":"Djulbegovic","year":"2025","journal-title":"Transl Vis Sci Technol"},{"key":"2025101704051719000_7.2.e001269.31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/07380577.2025.2488122","article-title":"A Three-Tiered Comprehensive Driving Evaluation Integrating a Driving Simulator Test for Drivers with Borderline Cognitive Fitness-to-Drive: Proof of Concept","volume":"39","author":"B\u00e9dard","year":"2025","journal-title":"Occup Ther Health Care"},{"key":"2025101704051719000_7.2.e001269.32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40120-017-0069-5","article-title":"Increasing Precision of Clinical Diagnosis of Alzheimer\u2019s Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data","volume":"6","author":"Sabbagh","year":"2017","journal-title":"Neurol Ther"},{"key":"2025101704051719000_7.2.e001269.33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2019.05.019","article-title":"Review: Patient-reported outcomes in multiple sclerosis care","volume":"33","author":"D\u2019Amico","year":"2019","journal-title":"Mult Scler Relat Disord"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:23:51Z","timestamp":1760700231000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjno-2025-001269"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001269","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}